Research programme : cancer therapeutics - Wuxi MTLH Biotechnology

Drug Profile

Research programme : cancer therapeutics - Wuxi MTLH Biotechnology

Alternative Names: MTLH-001-Wuxi; MTLH-002; MTLH-003; MTLH-004; MTLH001

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wuxi MTLH Biotechnology
  • Class Antineoplastics; Peptides; Proteins
  • Mechanism of Action ERBB 2 receptor antagonists; Platelet-derived growth factor receptor antagonists; Transforming growth factor beta modulators; Tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 25 Jan 2016 Early research in Cancer in China (unspecified route)
  • 25 Jan 2016 Wuxi MTLH Biotechnology has patent-protection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top